English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The clinical presentation of post-transplantation thrombotic microangiopathy (TMA) is variable. Often, TMA will manifest systemically as haemolytic-uraemic syndrome (HUS), with classic findings of renal failure, haemolytic anaemia, schistocytes and thrombocytopenia [1]. Localized and systemic TMA represent a spectrum of severity of the same disorder, not two different disorders with distinct pathophysiological states. Pre-transplantation HUS, anticardiolipin antibodies, acute rejection, cytomegalovirus (CMV) and some medications are associated with the development of TMA. Herein we report a patient who developed the signs and symptoms of de novo HUS and transplant renal artery thrombosis following switching from cyclosporin to tacrolimus.

nephrology, dialysis, transplantation/nephrology dialysis transplantation

Development of transplant renal artery thrombosis and signs of haemolytic-uraemic syndrome following the change from cyclosporin to tacrolimus in a renal transplant patient